氨溴特罗联合孟鲁司特治疗小儿咳嗽变异性哮喘的效果分析

Effect of ambroxol combined montelukast in treatment of children with cough variant asthma

目的探讨氨溴特罗结合孟鲁司特治疗小儿咳嗽变异性哮喘的临床作用及安全性。方法选取商丘市妇幼保健院2011年2月至2012年12月收治的60例咳嗽变异性哮喘的患儿,根据用药的不同随机分为氨溴特罗组、孟鲁司特组和氨溴特罗联合孟鲁司特组(联合用药组),每组各20例。观察患儿临床疗效和计算不同时间峰值呼气流速(PEF)变异率,以观察肺功能改变情况。结果两种药物单一治疗组患儿咳嗽改善情况无明显差异(P>0.05),发生咳嗽变异性哮喘率较高;但两种药物结合治疗组咳嗽间隔时间明显延长,且发生咳嗽变异性哮喘率明显低于前两组(P<0.05)。结论氨溴特罗联合孟鲁司特治疗小儿咳嗽变异性哮喘可有效改善临床症状,且安全、有效。

Objective To investigate the clinical effects and safety of combination of ambroxol and montelukast treatment of children with cough variant asthma. Methods Totally 60 cases of cough variant asthma in children Shangqiu City MCH February 2011 to December 2012 were treated, depending on the random drug into ammonia, bromine Castro group, montelukast group and ammonia bromine special Luo joint montelukast group （combination group ） 20 cases each. The clinical efficacy observed in children at different times and calculate the peak expiratory flow （PEF） variation rate in order to change the situation observed in lung function. Results The results of the two drugs in children with cough improvement monotherapy group had no significant difference （ P 〉 0.05 ）, a higher occurrence of cough variant asthma rates; But the two drugs combined treatment group was significantly longer intervals of cough and cough variant asthma rates occurred significantly lower than the first two groups （ P 〈 0. 05 ）. Conclusion Ambroxol Castro combined montelukast treatment of children with cough variant asthma can improve clinical symptoms, and Itis safe and effective.